Search Results for agency_names:"Drug Enforcement Administration"

In the Federal Register notice titled "Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order," the DEA sought to revoke Dr. Ibrahim Al-Qawaqneh's registration due to his exclusion from federal health care programs after pleading nolo contendere to a charge of offering unlawful Medi-Cal remuneration. Despite being given a chance to defend himself, the DEA found that Dr. Al-Qawaqneh failed to take full responsibility for his actions, which led to doubts about his trustworthiness. Consequently, his DEA Certificate of Registration was revoked to ensure compliance with laws regulating controlled substances.

Patheon Pharmaceuticals Inc. has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. The company plans to use these substances as Active Pharmaceutical Ingredients in FDA-approved medications. Anybody interested can submit comments or objections electronically by May 12, 2025, through the Federal eRulemaking Portal. Requests for a hearing regarding this application are also due by the same date.

In a decision by the Drug Enforcement Administration (DEA), Dr. Michael W. Carlton's Certificate of Registration was revoked due to inappropriate prescribing practices. The DEA found that Dr. Carlton issued 40 prescriptions for controlled substances without establishing a proper doctor-patient relationship and without conducting necessary physical exams, which violated federal and Arizona state laws. Dr. Carlton argued that his practice was standard at the outpatient treatment center where he worked, but the DEA's investigation and expert testimony showed that his actions fell below the standard of care. Consequently, the revocation was seen as necessary to protect public interest.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Dr. Matthew Okeke, who is based in Nevada. This order proposed revoking his DEA registration because he no longer has a valid state license or authority to handle controlled substances in Nevada. Dr. Okeke did not respond to the order, leading the DEA to proceed with final agency action to revoke his registration. The decision was signed by DEA Administrator Anne Milgram and is set to take effect on January 29, 2025.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Soroosh Armandi, D.O., proposing to revoke his DEA registration because he no longer has the authority to handle controlled substances in California. Despite being notified, Dr. Armandi did not request a hearing to contest this action. His California medical license has been revoked, making him ineligible to maintain a DEA registration. As a result, the DEA has decided to revoke his DEA Certificate of Registration and deny any pending applications for renewal or additional registrations in California.

Noramco Inc has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances, including synthetic versions of Marihuana Extract, Marihuana, and Tetrahydrocannabinols. The company intends to produce these substances as active pharmaceutical ingredients and reference standards for their customers. Interested parties are invited to submit comments, objections, or a request for a hearing regarding this application by April 6, 2021. Written comments should be sent to the DEA's Federal Register Representative in Springfield, Virginia.

Restek Corporation has applied to be registered as a bulk manufacturer of certain controlled substances. The application was submitted to the Drug Enforcement Administration on February 19, 2025, and the company plans to produce synthetic versions of substances like Marihuana and Tetrahydrocannabinols for specific purposes. Interested parties can file comments or objections, or request a hearing on this registration by June 17, 2025. All submissions must be made through the Federal eRulemaking Portal.

Catalent Greenville, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company plans to use these substances for developing bulk dosage formulations for research and clinical trials. People or organizations that have an interest in this matter can submit comments or request a hearing by March 3, 2025. Submissions can be made through the Federal eRulemaking Portal, and hearings request should be sent to the DEA at specified addresses.

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import these substances solely for clinical trials. Other types of uses or commercial sales are not allowed under this registration. Interested parties can submit comments or objections electronically by April 16, 2025, and can also request a hearing on the application by the same date.

Patheon API Manufacturing, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. The company intends to produce these substances as Active Pharmaceutical Ingredients (APIs) for its customers, specifically focusing on synthetic tetrahydrocannabinols. The public, including existing manufacturers and applicants, may submit comments or request a hearing on this application by April 20, 2021.